The Evaluation of Laser Lancing Devices in Adult Type 2 Diabetes Patients

NCT ID: NCT05251506

Last Updated: 2022-02-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-08-10

Study Completion Date

2022-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Self monitoring of blood glucose level is crucial in diabetes management, but currently available methods, lancet, have shown low compliance of self monitoring of blood glucose because of pain, keratinization of finger tip, secondary infection. The purpose of this study is evaluating laser lancing device which cause much less pain than lancet to increase compliance of blood sugar checking, and to establish self monitoring system for patients of chronic diseases.

The investigators recruit total of 80 type 2 diabetes patients who visit Korea University Medical center Guro and Ansan hospital. HbA1c level of subject is more than 6.5% and less than 8.5%, and their age is above 20 years and under 80 years. Subjects are randomly distributed in group A or B. Group A subjects use laser device to check blood glucose for 2 months, then take a month for wash out period. After wash out period, participants use lancet for following 2 months. Group B perform the process vice versa. The investigators evaluate the number of blood glucose measurement, HbA1c, diabetes distress scale, average pain score, average satisfaction score from each group.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Self monitoring of blood glucose level is crucial in diabetes management, so it is important to increase compliance of blood glucose checking. Lancet which is currently available methods have shown low compliance of self monitoring of blood glucose, since it causes pain, keratinization of finger tip, secondary infection. The purpose of this study is evaluating laser lancing device which cause much less pain than lancet to increase compliance of blood sugar checking, and to establish self monitoring system for patients of chronic diseases.

The investigators recruit total of 80 subjects who visit Korea University Medical center Guro and Ansan hospital. Study subject are type 2 diabetes whose glycated hemoglobin level is more than 6.5% and less than 8.5%, and whose age is more than 20 years and under 80 years. Subjects are randomly distributed in group A or B. Group A subjects use laser device to check blood glucose for 2 months, then take a month for wash out period. After wash out period, participants use lancet for following 2 months. Group B subjects use lancet first, then have a month for wash out period, after then, switch to laser device afterwards. During washout period, participants use usual glucose checking method which subjects had used. The investigators evaluate the number of blood glucose measurement, glycated hemoglobin, diabetes distress scale, average pain score, average satisfaction score from each group. Also the investigators compare blood glucose, liver function test, lipid level between values from one hand measured by lancet, and values from the other hand measured by laser lancing device.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 2 Diabetes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Each group use lancet (or laser) for first 2 months, take wash out period for 1month, then use laser (or lancet) for another 2 months.
Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

laser lancing device (LMT-1000) first user

Subjects measure blood glucose using laser lancing device (LMT-1000) for first 2 months, then take a month for wash out period, after that do using lancet for following 2 months.

Group Type EXPERIMENTAL

laser lancing device or lancet for blood glucose level measurement

Intervention Type DEVICE

Subjects measure blood glucose level using laser lancing device (LMT-1000) and lancet for 2 months each.

lancet first user

Subjects measure blood glucose using lancet for first 2 months, , then take a month for wash out period, after that do using laser lancing device (LMT-1000) for following 2 months.

Group Type ACTIVE_COMPARATOR

laser lancing device or lancet for blood glucose level measurement

Intervention Type DEVICE

Subjects measure blood glucose level using laser lancing device (LMT-1000) and lancet for 2 months each.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

laser lancing device or lancet for blood glucose level measurement

Subjects measure blood glucose level using laser lancing device (LMT-1000) and lancet for 2 months each.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Type 2 diabetes patients who visit Korea University medical center, Guro hospital, Ansan hospital
* Patients with Hba1c more than 6.5% and less than 8.5%
* Adults who are able to measure blood glucose level by themselves
* Adults who are able to lance their same finger from both hands
* Adults who comprehend risk of participating in the clinical research, who are able to communicate each other, who are able to follow rules of clinical research
* Subjects who decide to participate in the clinical research voluntarily and sign in the consent format after being informed purposes, methods, expectations of the clinical research

Exclusion Criteria

* Subject whose age is younger than 19 or older than 80
* students of research institutes
* Pregnant and lactating women
* Subjects who are not able to make decision
* Subjects who are in emergency or being hospitalized
* Subjects who cannot lance sane finger from both hands
* Subjects who are infected by HIV in hospital records
* Subjects who have thrombocytopenia, coagulation disorder or haemophilia
* Subjects who are incompatible for clinical research as researcher evaluated
Minimum Eligible Age

20 Years

Maximum Eligible Age

79 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Korea Medical Device Development Fund

UNKNOWN

Sponsor Role collaborator

Korea University Guro Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Hye Jin Yoo

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Korea University medical center

Seoul, , South Korea

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

South Korea

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Min Jeong Park

Role: CONTACT

+82-10-7271-3805

Hye Jin Yoo

Role: CONTACT

+82-10-8951-9451

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Min Jeong Park, M.D.

Role: primary

+82-10-7271-3805

Hye Jin Yoo, M.D. Ph.D

Role: backup

+82-10-8951-9451

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

K2021-1520-002

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.